These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 35295080)

  • 21. Beyond SARS-CoV2, the role of viruses in the pathogenesis of hematologic malignancies.
    Wiestner A
    Semin Hematol; 2022 Oct; 59(4):175-176. PubMed ID: 36805884
    [No Abstract]   [Full Text] [Related]  

  • 22. Weathering the storm: COVID-19 infection in patients with hematological malignancies.
    Wang LQ; Tan Su Yin E; Wei GQ; Hu YX; Nagler A; Huang H
    J Zhejiang Univ Sci B; 2020 Dec.; 21(12):921-939. PubMed ID: 33843158
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improvement in mortality of hospitalized patients with hematological malignancies in the 2nd wave of COVID-19 in the UK: experience of a large London NHS trust.
    Hinton R; Nesr G; Garnett C; Foldes D; McCay JJR; Medland R; Kagdi H; Katsomitrou V; Sim HW; Gandhi S; Parcharidou A; Arami S
    Leuk Lymphoma; 2022 Jan; 63(1):227-230. PubMed ID: 34470547
    [No Abstract]   [Full Text] [Related]  

  • 24. Strategic plan for management of COVID-19 in paediatric haematology and oncology departments.
    He Y; Lin Z; Tang D; Yang Y; Wang T; Yang M
    Lancet Haematol; 2020 May; 7(5):e359-e362. PubMed ID: 32246912
    [No Abstract]   [Full Text] [Related]  

  • 25. Clinical Characteristics and Outcomes of COVID-19 in Turkish Patients with Hematological Malignancies.
    Civriz Bozdağ S; Cengiz Seval G; Yönal Hindilerden İ; Hindilerden F; Andıç N; Baydar M; Aydın Kaynar L; Toprak SK; Göksoy HS; Balık Aydın B; Demirci U; Can F; Özkocaman V; Gündüz E; Güven ZT; Özkurt ZN; Demircioğlu S; Beksaç M; İnce İ; Yılmaz U; Eroğlu Küçükdiler H; Abishov E; Yavuz B; Ataş Ü; Mutlu YG; Baş V; Özkalemkaş F; Üsküdar Teke H; Gürsoy V; Çelik S; Çiftçiler R; Yağcı M; Topçuoğlu P; Çeneli Ö; Abbasov H; Selim C; Ar MC; Yücel OK; Sadri S; Albayrak C; Demir AM; Güler N; Keklik M; Terzi H; Doğan A; Yegin ZA; Kurt Yüksel M; Sadri S; Yavaşoğlu İ; Beköz HS; Aksu T; Maral S; Erol V; Kaynar L; İlhan O; Bolaman AZ; Sevindik ÖG; Akyay A; Özcan M; Gürman G; Ünal Ş; Yavuz Y; Diz Küçükkaya R; Özsan GH
    Turk J Haematol; 2022 Feb; 39(1):43-54. PubMed ID: 34521187
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SARS-CoV-2 Viral Load Predicts Mortality in Patients with and without Cancer Who Are Hospitalized with COVID-19.
    Westblade LF; Brar G; Pinheiro LC; Paidoussis D; Rajan M; Martin P; Goyal P; Sepulveda JL; Zhang L; George G; Liu D; Whittier S; Plate M; Small CB; Rand JH; Cushing MM; Walsh TJ; Cooke J; Safford MM; Loda M; Satlin MJ
    Cancer Cell; 2020 Nov; 38(5):661-671.e2. PubMed ID: 32997958
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Infections with the SARS-CoV-2 Omicron variant show a similar outcome as infections with the previous variants in patients with hematologic malignancies.
    Taenaka R; Obara T; Kohno K; Aoki K; Ogawa R
    Ann Hematol; 2022 Aug; 101(8):1877-1878. PubMed ID: 35391563
    [No Abstract]   [Full Text] [Related]  

  • 28. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies.
    Greenberger LM; Saltzman LA; Senefeld JW; Johnson PW; DeGennaro LJ; Nichols GL
    Cancer Cell; 2021 Aug; 39(8):1031-1033. PubMed ID: 34331856
    [No Abstract]   [Full Text] [Related]  

  • 30. Should we screen patients with hematologic malignancies for COVID-19?
    Rassy E; Khoury-Abboud RM; Ibrahim N; Assi T; Samra B; Hanna C; Karak FE; Ghosn M
    Hematol Oncol; 2020 Dec; 38(5):648-653. PubMed ID: 32779823
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcome of hospitalized patients with hematological malignancies and COVID-19 infection in a large urban healthcare trust in the United Kingdom.
    Garnett C; Foldes D; Bailey C; Nesr G; Hui T; Hinton R; Gurung K; Phillips J; Saleem Z; Koshy R; Aduwa E; Colis M; Bimolah R; Katsomitrou V; Arami S; Kagdi H
    Leuk Lymphoma; 2021 Feb; 62(2):469-472. PubMed ID: 33167718
    [No Abstract]   [Full Text] [Related]  

  • 32. Clinical course and risk factors for mortality from COVID-19 in patients with haematological malignancies.
    Sanchez-Pina JM; Rodríguez Rodriguez M; Castro Quismondo N; Gil Manso R; Colmenares R; Gil Alos D; Paciello ML; Zafra D; Garcia-Sanchez C; Villegas C; Cuellar C; Carreño-Tarragona G; Zamanillo I; Poza M; Iñiguez R; Gutierrez X; Alonso R; Rodríguez A; Folgueira MD; Delgado R; Ferrari JM; Lizasoain M; Aguado JM; Ayala R; Martinez-Lopez J; Calbacho M
    Eur J Haematol; 2020 Nov; 105(5):597-607. PubMed ID: 32710500
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prolonged SARS-CoV-2 cell culture replication in respiratory samples from patients with severe COVID-19.
    Folgueira MD; Luczkowiak J; Lasala F; Pérez-Rivilla A; Delgado R
    Clin Microbiol Infect; 2021 Jun; 27(6):886-891. PubMed ID: 33631334
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Blunted humoral response after mRNA vaccine in patients with haematological malignancies.
    Kamboj M
    Lancet Haematol; 2021 Aug; 8(8):e540-e542. PubMed ID: 34224666
    [No Abstract]   [Full Text] [Related]  

  • 35. The outcome ofancy. COVID-19 in patients with hematological malign.
    Yigenoglu TN; Bascı S; Dal MS; Korkmaz S; Turgut B; Altuntas F
    J Med Virol; 2021 Mar; 93(3):1255. PubMed ID: 33064307
    [No Abstract]   [Full Text] [Related]  

  • 36. Balancing risk and benefit during coronavirus.
    Sehn LH
    Blood; 2020 May; 135(21):1817. PubMed ID: 32275744
    [No Abstract]   [Full Text] [Related]  

  • 37. Virological assessment of hospitalized patients with COVID-2019.
    Wölfel R; Corman VM; Guggemos W; Seilmaier M; Zange S; Müller MA; Niemeyer D; Jones TC; Vollmar P; Rothe C; Hoelscher M; Bleicker T; Brünink S; Schneider J; Ehmann R; Zwirglmaier K; Drosten C; Wendtner C
    Nature; 2020 May; 581(7809):465-469. PubMed ID: 32235945
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunogenicity of the COVID-19 Two-Vaccination Series Among Hematologic Malignancies: Report of Three Cases of Breakthrough Infection.
    Pasikhova Y; Morrison AR; Katzman JH; Syed M
    Cancer Control; 2022; 29():10732748211070720. PubMed ID: 35001670
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimizing Administration of CAR T-Cell Therapy During the COVID-19 Pandemic.
    Bishop MR
    Clin Adv Hematol Oncol; 2020 Jul; 18(7):400-403. PubMed ID: 32903251
    [No Abstract]   [Full Text] [Related]  

  • 40. Imaging of Hematological Patients in the Era of COVID-19.
    Eshet Y; Avigdor A; Kedmi M; Tau N
    Acta Haematol; 2022; 145(3):267-274. PubMed ID: 35100592
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.